GlassScriptPhysician profile
Noor Chima
NPI 1578079877
$2,862.30
in general payments reported to CMS, 2019-2025
14 companies · $74.02 in 2025
The $74.02 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $803 · 2023: $936 · 2024: $828 · 2025: $74.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.69 |
| Education | $365.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $662.51 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $385.55 | 2021-2025 | Eliquis, Camzyos |
| Heartflow, INC. | $292.25 | 2024 | |
| Abiomed | $234.75 | 2022-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.28 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $216.84 | 2021-2023 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $204.83 | 2022-2024 | |
| Medtronic, INC. | $176.18 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.74 | 2022-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $108.00 | 2023 | Inpefa |
| Boston Scientific Corporation | $105.91 | 2024 | |
| Pfizer INC. | $74.72 | 2022-2023 | |
| Genzyme Corporation | $28.71 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noor Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.